Immunstimulative CpG-Oligodeoxynukleotide (CpG-ODN) im orthotopen murinen Transitionalzellkarzinom (TCC)-Modell

[1]  K. Heeg,et al.  Immunostimulatory CpG Oligonucleotides Reduce Tumor Burden after Intravesical Administration in an Orthotopic Murine Bladder Cancer Model , 2005, Tumor Biology.

[2]  M. Ernst,et al.  Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro , 1993, Cancer Immunology, Immunotherapy.

[3]  F. Debruyne,et al.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer , 2005, Cancer Immunology, Immunotherapy.

[4]  A. Böhle,et al.  Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.

[5]  M. Stöckle,et al.  [EAU Recommendations 2001. "Guidelines on bladder cancer"]. , 2002, Progrès en urologie (Paris).

[6]  Gerhard Jakse,et al.  Guidelines on bladder cancer. , 2002, European urology.

[7]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[8]  A. Zlotta,et al.  What are the immunologically active components of Bacille Calmette‐Guérin in therapy of superficial bladder cancer? , 2000, International journal of cancer.

[9]  K. Heeg,et al.  CpG DNA as a Th1 Trigger , 2000, International Archives of Allergy and Immunology.

[10]  A. Böhle.  BCG’s Mechanism of Action – Increasing our Understanding , 1999, European Urology.